Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181205 | 0.82 | ALDH1A1 (0.38) | GPR119KCNH2ALDH1A1MAPTKLKB1 | |
| SCHEMBL10181179 | 0.82 | GPR119 (0.49) | GPR119 | |
| SCHEMBL1950704 | 0.80 | GPR119 (0.72) | GPR119ALDH1A1MAPTTDP1 | |
| SCHEMBL10203528 | 0.79 | GPR119 (0.52) | GPR119KCNH2 | |
| SCHEMBL10181034 | 0.76 | GPR119 (0.45) | GPR119 | |
| SCHEMBL14142230 | 0.76 | GPR119 (0.48) | GPR119KCNH2 | |
| SCHEMBL12471096 | 0.75 | GPR119 (0.51) | GPR119 | |
| SCHEMBL14158932 | 0.74 | GPR119 (0.52) | GPR119KCNH2ALDH1A1HSP90AA1MAPT | |
| SCHEMBL1577705 | 0.74 | GPR119 (0.62) | GPR119ALDH1A1MAPT | |
| SCHEMBL1577956 | 0.72 | GPR119 (0.60) | GPR119ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | GPR119 1/4885KCNH2 484/4885SCARB1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.